Trial Profile
Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of CAD-1883 in Adults With Spinocerebellar Ataxia (Synchrony-1)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2021
Price :
$35
*
At a glance
- Drugs Rimtuzalcap (Primary)
- Indications Spinocerebellar ataxias
- Focus Adverse reactions
- Acronyms Synchrony-1
- Sponsors Cadent Therapeutics
- 05 Apr 2021 Planned initiation date changed from 1 Aug 2020 to 1 Jun 2021.
- 05 Apr 2021 Status changed from suspended to withdrawn prior to enrolment.
- 25 Nov 2020 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.